Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission
- PMID: 27983886
- DOI: 10.1089/jayao.2016.0060
Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission
Abstract
Purpose: Adolescents and young adults (AYAs) with cancer are a unique group of patients in terms of disease incidence and biology, outcome, and psychosocial needs. This study aims to correlate the risk of graft-versus-host disease (GvHD) and age in a population of children and young adults with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT) in first complete remission (CR).
Methods: We analyzed the outcome of 153 consecutive children (<15 years), AYAs (15-24 years), and adults (25-35 years) with lymphoblastic or myeloid acute leukemia in first CR who underwent HSCT with matched donors after myeloablative conditioning. GvHD prophylaxis was methotrexate and cyclosporine A (CsA) in all patients.
Results: The cumulative incidence of grade II-IV acute GvHD (aGvHD) was significantly higher in AYA patients than in children (subdistribution hazard ratio (SHR), 2.04, p = 0.005) or adults (SHR 1.59, p = 0.048). Both gut and skin aGvHD occurred more frequently in AYA patients. Increasing CsA blood levels with age could not fully account for this difference. No difference in terms of grade III-IV aGvHD was observed. Chronic GvHD was more frequent in AYAs (SHR 2.81, p = 0.007) and adults (SHR 2.31, p = 0.033) than in children. No difference in terms of nonrelated mortality and overall survival was observed among the age subgroups.
Conclusion: Since GvHD occurrence is strongly correlated to quality of life, specific attention should be paid to AYAs undergoing HSCT. Further studies should investigate the reasons for the excess of GvHD observed in this population.
Keywords: acute lymphoblastic leukemia; acute myeloid leukemia; allogeneic stem cell transplantation; graft-versus-host disease.
Similar articles
-
[Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].Ai Zheng. 2006 Aug;25(8):1019-22. Ai Zheng. 2006. PMID: 16965686 Chinese.
-
Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.Am J Hematol. 2015 May;90(5):392-9. doi: 10.1002/ajh.23955. Epub 2015 Apr 8. Am J Hematol. 2015. PMID: 25615933
-
Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.Bone Marrow Transplant. 2016 May;51(5):698-704. doi: 10.1038/bmt.2015.350. Epub 2016 Jan 25. Bone Marrow Transplant. 2016. PMID: 26808568
-
Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.Transplantation. 2020 Feb;104(2):428-436. doi: 10.1097/TP.0000000000002836. Transplantation. 2020. PMID: 31283681
-
Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group.Int J Hematol. 2004 Jan;79(1):79-84. doi: 10.1007/BF02983538. Int J Hematol. 2004. PMID: 14979483 Review.
Cited by
-
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.Transplant Cell Ther. 2024 Jun;30(6):603.e1-603.e11. doi: 10.1016/j.jtct.2024.03.022. Epub 2024 Mar 27. Transplant Cell Ther. 2024. PMID: 38548227 Free PMC article.
-
Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide-based regimen for prevention of graft-versus-host disease in haploidentical peripheral blood stem cell transplantation for pediatric patients with hematologic malignancies.Ann Hematol. 2024 Sep;103(9):3765-3774. doi: 10.1007/s00277-024-05883-w. Epub 2024 Jul 10. Ann Hematol. 2024. PMID: 38981923
-
Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.Transplant Cell Ther. 2023 Feb;29(2):123.e1-123.e10. doi: 10.1016/j.jtct.2022.11.019. Epub 2022 Nov 26. Transplant Cell Ther. 2023. PMID: 36442769 Free PMC article.
-
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.Am J Hematol. 2018 Oct;93(10):1254-1266. doi: 10.1002/ajh.25229. Epub 2018 Sep 3. Am J Hematol. 2018. PMID: 30058716 Free PMC article. Review.
-
Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population.Ther Adv Hematol. 2020 Feb 3;11:2040620720903531. doi: 10.1177/2040620720903531. eCollection 2020. Ther Adv Hematol. 2020. PMID: 32071710 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical